

FOR IMMEDIATE RELEASE

Gentel® Biosciences Contact:

G. Randall Durnell

VP, Commercial Operations

randydurnell@gentelbio.com

(608) 441-2904



**GENTEL BIOSCIENCES PLACES FIRST PROTEIN ARRAY READER
AT CPGR, SOUTH AFRICA**

MADISON, WI & Cape Town, RSA (August 19, 2008) — Gentel® Biosciences, Inc., a protein microarray life sciences company, announces it has placed its first APiX™ Colorimetric Protein Array Reader at the Centre for Proteomic and Genomic Research (CPGR) in Cape Town, South Africa.

The Gentel reader integrates a novel colorimetric detection technology with a newly developed 96-well plate microarray format, APiX 96. Gentel's novel transparent nitrocellulose-coated plastic substrate serves as the surface chemistry for the instrument.

"Because of its simplicity, the Gentel colorimetric system has the potential to overcome the relatively high cost concerns of existing microarray applications. This creates an opportunity for developing affordable while at the same time reliable assays, something that is of critical importance in emerging markets such as South Africa" said Dr. Reinhard Hiller, Managing Director of the CPGR.

Gentel's APiX colorimetric detection technology is a patented method in which gold particle-enhanced silver crystal deposition is used for detection and quantification on microarrays. Because silver deposition is highly localized, each microplate well can contain as many as several hundred protein spots.

"Gold particle-enhanced silver crystal deposition enables multiplexed sandwich immunoassays with superior sensitivity and reproducibility compared to fluorescence-based microarrays and ELISA" said Bryce Nelson, Gentel's VP of Research and Development. "We believe a 96-well colorimetric system is well-positioned for customers seeking to migrate from multiple ELISAs to multiplexed assays."

Gentel® Biosciences, Inc. · 5500 Nobel Dr., Ste 230 · Madison, WI 53711

Tel: (608) 441-2904 · Fax: (608) 441-2970 · info@gentelbio.com · www.gentelbio.com

The CPGR was created with a vision of establishing a modern, world-class, high-throughput biological research facility that serves the needs of the life science and biotech communities in South Africa by providing state-of-the-art analytical services, technical expertise, project support and collaborative research capabilities in the genomics and proteomics sectors.

“Gentel’s new platform promises to combine the benefits of existing high-throughput single-plex diagnostic systems, novel array formats, and low-cost tests based on lateral flow assays,” added Dr. Hiller. “Using the system, we intend to generate proof-of-concept data for a number of potential diagnostic applications in key disease areas such as TB, HIV/AIDS, malaria, asthma/COPD and cancer, amongst others.”

Gentel is currently seeking early access partners for co-development and commercialization of novel biomarker panels.

ABOUT GENTEL BIOSCIENCES

Gentel Biosciences, Inc. is a protein microarray company whose mission is to deliver the most reliable tools, kits and services for performing multiplex protein measurements to the life science community. Visit www.gentelbio.com for more information.

ABOUT CPGR

The Centre for Proteomic & Genomic Research (CPGR) is an integrated core technology facility, founded in South Africa in 2006 as a not-for-profit organization through a grant provided by the Department of Science & Technology (DST) by way of its vehicles the Cape Biotech Trust (CBT) and PlantBio (PB). Visit www.cpgr.org.za for more information.

###

Gentel® Biosciences, Inc. · 5500 Nobel Dr., Ste 230 · Madison, WI 53711

Tel: (608) 441-2904 · Fax: (608) 441-2970 · info@gentelbio.com · www.gentelbio.com